[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.52.4. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
May 2017

Therapeutic and Preventive Implications of Moonshot in Hereditary Cancer Syndromes

Author Affiliations
  • 1Department of Internal Medicine, Creighton University, Omaha, Nebraska
  • 2Department of Preventive Medicine, Creighton University, Omaha, Nebraska
JAMA Oncol. 2017;3(5):592-593. doi:10.1001/jamaoncol.2016.3046

An announcement was made regarding the initiation of a “moonshot” approach to the multifaceted cancer problems with the intent on reducing cancer mortality in the United States by accelerating cancer research to discover more therapies and focusing on finding new ways to prevent cancer and detect it in an early stage before it spreads. President Obama’s proposed fiscal year 2017 budget includes $1 billion for eliminating cancer. This initiative has led to the belief that concentrating on treatment is a limited approach to the overall reduction of cancer mortality, considering the success of cancer research in prevention.1 However, a powerful method for cancer prevention and survival has been the discipline of hereditary cancer syndromes. In this article, we discuss the significance of investing billions of dollars in genomic sequencing and the implications of finding a hereditary mutation in patients with metastatic cancer using next-generation sequencing (NGS).

×